Sign In
Buy NCNA
$2.03
-0.0400 (-1.93%)
At Close: Jun 03, 2026
NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update
04:01pm, Thursday, 19'th Aug 2021
EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinic
NuCana: Starting A Speculative Position At An Astonishing Risk-Reward
05:25am, Saturday, 05'th Jun 2021
NuCana has been on my watch list over the past year due to its intriguing ProTide platform technology, which could generate multiple oncology drugs that can outperform the current standard of care. Th
NuCana Reports First Quarter 2021 Financial Results and Provides Business Update
04:01pm, Wednesday, 19'th May 2021
Presented Encouraging Clinical Data at ASCO-GI and AACR
NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit
08:00am, Wednesday, 28'th Apr 2021
EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host o
NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
08:30am, Saturday, 10'th Apr 2021
EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting
NuCana Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
04:01pm, Thursday, 04'th Mar 2021
Presented Encouraging Clinical Data for NUC-3373 and NUC-7738
3 Biotech Stocks That Jumped Last Week
09:59am, Sunday, 17'th Jan 2021
Find out what led to the biotech industry's biggest gains.
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
08:01am, Friday, 15'th Jan 2021
Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy
NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session
09:47am, Monday, 11'th Jan 2021
NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
NuCana Appoints Andrew Kay as Board Chairman
04:01pm, Monday, 21'st Dec 2020
Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors
Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed
NuCana Reports Third Quarter 2020 Financial Results and Provides Business Update
04:01pm, Thursday, 19'th Nov 2020
Completed Successful $ 8 0 million Public Offering
NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
04:01pm, Tuesday, 17'th Nov 2020
EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present
NuCana to Present at the Jefferies Virtual London Healthcare Conference
04:01pm, Thursday, 12'th Nov 2020
EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present
Nigeria loses N1.2trn to ASUU strikes - Businessday NG
11:36pm, Sunday, 04'th Oct 2020
The indefinite strike, which commenced on March 29, according to sources at the National Universities Commission (NUC) is the longest in the history of ASUU strikes.
